{"url_path":"/sec/mnpr/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-016982-index.html","accession_number":"0001437749-26-016982","cik":"0001645469","ticker":"MNPR","issuer_name":"Monopar Therapeutics","edgar_url":"https://www.sec.gov/Archives/edgar/data/1645469/0001437749-26-016982-index.html","primary_entity_key":"0001645469","primary_entity_name":"Monopar Therapeutics"},"word_count":197,"has_tables":true,"body_markdown":"**Item 6. Exhibits**\n\n \n\nThe following exhibits are filed as part of this Quarterly Report on Form 10-Q.\n\n \n\n**Exhibit**\n\n \n\n**Document**\n\n \n\n**Incorporated by Reference From:**\n\n[31.1](ex_942709.htm)\n\n \n\n[Certification of Chandler D. Robinson, Chief Executive Officer](ex_942709.htm)\n\n \n\nFiled herewith\n\n[31.2](ex_942710.htm)\n\n \n\n[Certification of Quan Vu, Chief Financial Officer](ex_942710.htm)\n\n \n\nFiled herewith\n\n[32.1](ex_942711.htm)\n\n \n\n[Certification of Chandler D. Robinson, Chief Executive Officer and Quan Vu, Chief Financial Officer](ex_942711.htm)\n\n \n\nFiled herewith\n\n101.INS\n\n \n\nInline XBRL Instance Document\n\n \n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema\n\n \n \n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase\n\n \n \n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase\n\n \n \n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase\n\n \n \n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase\n\n \n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)\n\n \n \n\n \n\n \n\n34\n\n[Table of Contents](#toc)\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n \n\n**MONOPAR THERAPEUTICS INC.**\n\n \n\n \n \n \n \n\nDated: May 14, 2026\n\nBy:\n\n/s/ Chandler D. Robinson\n\n \n\n \n\nName:\n\nChandler D. Robinson\n\n \n\n \n\nTitle:\n\nChief Executive Officer and Director (Principal Executive Officer)\n\n \n\n \n\n \n\n**MONOPAR THERAPEUTICS INC.**\n\n \n\n \n \n \n \n\nDated: May 14, 2026\n\nBy:\n\n/s/ Quan Vu\n\n \n\n \n\nName:\n\nQuan Vu\n \n\n \n\nTitle:\n\nChief Financial Officer (Principal Financial Officer)\n\n \n\n \n\n35"}